Description
Alecinix 150 MG (Alectinib) is an oral, second-generation, highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) supplied as a 150 mg capsule in a 120’s pack and manufactured by Beacon Pharmaceuticals Ltd., Bangladesh. Its active ingredient, alectinib, potently and selectively inhibits the ALK kinase domain including a broad spectrum of crizotinib-resistant ALK mutations while demonstrating exceptional central nervous system (CNS) penetration, a clinically critical attribute in ALK-positive non-small cell lung cancer (NSCLC) where brain metastases represent one of the most frequent and devastating sites of disease progression.
Alecinix 150 MG (Alectinib) is indicated for the first-line treatment of adults with ALK-positive advanced NSCLC, for adults with ALK-positive advanced NSCLC previously treated with crizotinib, and following the landmark April 2024 FDA approval for the adjuvant treatment of adults with completely resected stage IB (tumours ≥4 cm) to IIIA ALK-positive NSCLC. In the definitive head-to-head ALEX Phase III trial, alectinib delivered a final median overall survival of 81.1 months versus 54.2 months with crizotinib (HR 0.78; 95% CI 0.56–1.08) alongside a median progression-free survival of 34.8 months versus 10.9 months establishing alectinib as the global standard of care for first-line ALK-positive NSCLC. Searching for Alecinix 150 MG Alectinib? Mediaid Pharmacy lists this product within its comprehensive lung cancer medicines portfolio and ships it worldwide.
Basic Product Information of Alecinix 150 MG (Alectinib)
| Brand Name | Alecinix 150 MG (Alectinib) |
| Product Name | Alecinix |
| Generic Name | Alectinib INN |
| Drug Class | Second-Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor (TKI); CNS-Active Targeted Thoracic Oncology Agent |
| Formulation | Capsule |
| Available Strength | 150 mg |
| Available Pack Size | 120’s (120 capsules per pack) |
| Primary Indication | First-line treatment of adults with ALK-positive advanced NSCLC; ALK-positive advanced NSCLC previously treated with crizotinib; adjuvant treatment of adults with completely resected stage IB (≥4 cm) to IIIA ALK-positive NSCLC |
| Manufacturer | Beacon Pharmaceuticals Ltd., Bangladesh |
| Originator Reference Brand | Alecensa (alectinib) by Roche / Genentech |
| Registrations | Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at room temperature (below 30°C) in a dry place, away from light and moisture. Keep out of the reach of children. |
How Alecinix 150 MG (Alectinib) Works: Selective ALK Inhibition with Superior CNS Penetration in ALK-Positive NSCLC
Alectinib, the active ingredient in Alecinix 150 MG, is a second-generation, highly selective, orally bioavailable small-molecule inhibitor of anaplastic lymphoma kinase (ALK) a receptor tyrosine kinase that, when aberrantly activated through chromosomal rearrangement (most commonly the EML4-ALK fusion), drives oncogenic signalling in a subset of NSCLC tumours. An ALK tyrosine kinase inhibitor (ALK TKI) refers to a class of targeted oncology drugs that block ALK kinase activity, thereby disrupting the downstream RAS/ERK, PI3K/AKT, and JAK/STAT3 signalling cascades that sustain malignant cell survival, proliferation, and metastasis in ALK-rearranged NSCLC. Alectinib potently inhibits the ALK kinase domain achieving greater than 10-fold more potent ALK inhibition compared with the first-generation ALK inhibitor crizotinib and retains activity against a broad panel of crizotinib-resistant ALK secondary mutations, including L1196M, G1269A, C1156Y, F1174L, and I1171T, which represent the primary mechanisms of acquired resistance to first-line crizotinib therapy.
A defining pharmacological advantage of alectinib is its exceptional central nervous system (CNS) penetration. CNS metastases develop in up to 46% of patients with ALK-positive advanced NSCLC within the first two years of first-generation crizotinib therapy, representing one of the most clinically significant limitations of first-generation treatment. Alectinib achieves cerebrospinal fluid (CSF) concentrations that approximate estimated free plasma concentrations, enabling effective suppression of intracranial ALK-driven tumour growth a pharmacokinetic and pharmacodynamic advantage that has translated directly into significantly reduced rates of CNS progression in randomised Phase III trials. In the ALEX trial, alectinib reduced the risk of CNS progression or death by 84% versus crizotinib (HR 0.16; 95% CI 0.10–0.28; p<0.0001) a mechanistically consistent outcome of its superior CNS bioavailability. Oncologists building comprehensive lung cancer treatment programmes can review the complete range of lung cancer medicines at Mediaid Pharmacy for companion and supportive therapies.
In the pivotal head-to-head ALEX Phase III trial the first global randomised study comparing a second-generation ALK TKI directly with crizotinib as first-line therapy in advanced ALK-positive NSCLC alectinib at 600 mg twice daily (four 150 mg capsules twice daily with food) delivered a final median overall survival of 81.1 months versus 54.2 months with crizotinib (HR 0.78; 95% CI 0.56–1.08; data cutoff April 2025) and a final median progression-free survival of 34.8 months versus 10.9 months. The 5-year overall survival rate was 62.5% with alectinib versus 45.5% with crizotinib, and the median duration of response in confirmed responders was 42.3 months versus 11.1 months (HR 0.41; 95% CI 0.30–0.56) establishing alectinib as the current global standard of care for first-line ALK-positive NSCLC. Alectinib is continued until disease progression or unacceptable toxicity; in the adjuvant setting, the treatment duration is two years following complete tumour resection.
Approved Indications of Alectinib (Reference Label for Alecinix 150 MG (Alectinib))
Alectinib, the active ingredient in Alecinix 150 MG, is approved internationally across three ALK-positive NSCLC settings first-line advanced disease, crizotinib-pretreated advanced disease, and adjuvant post-resection treatment. Prescribers should confirm the exact locally approved indications on the Alecinix product label before initiating therapy.
|
First-Line Advanced ALK-Positive NSCLC and Crizotinib-Pretreated Advanced ALK-Positive NSCLC Alectinib is indicated for the first-line treatment of adults with ALK-positive advanced NSCLC and for adults with ALK-positive advanced NSCLC previously treated with crizotinib. In the ALEX Phase III trial (treatment-naïve advanced ALK+ NSCLC, n=303), alectinib 600 mg twice daily delivered a final median overall survival of 81.1 months versus 54.2 months with crizotinib (HR 0.78; data cutoff April 2025), a final median PFS of 34.8 months versus 10.9 months, and a 5-year OS rate of 62.5% versus 45.5% confirming alectinib as the preferred standard-of-care first-line ALK TKI in advanced ALK-positive NSCLC with both superior systemic and intracranial disease control. |
Adjuvant Treatment Completely Resected Stage IB (≥4 cm) to IIIA ALK-Positive NSCLC (FDA-Approved April 2024) Alectinib received FDA approval in April 2024 as the first adjuvant targeted therapy for completely resected ALK-positive NSCLC, based on the Phase III ALINA trial (n=257). Adjuvant alectinib reduced the risk of disease recurrence or death by 76% compared with platinum-based chemotherapy (HR 0.24; 95% CI 0.13–0.43; p<0.0001) in patients with stage IB (tumours ≥4 cm) to IIIA disease. CNS disease-free survival was also significantly improved (HR 0.22; 95% CI 0.08–0.58), with a 4-year CNS DFS rate of 90.4% versus 76.1% with chemotherapy positioning adjuvant alectinib as a therapeutic breakthrough in preventing CNS recurrence following resection. |
Key Clinical Benefits of Alecinix 150 MG (Alectinib)
|
81.1-Month Median Overall Survival and 34.8-Month Median PFS Establishing First-Line Superiority Over Crizotinib Final data from the ALEX Phase III trial (data cutoff April 2025) confirmed alectinib 600 mg twice daily delivered a median OS of 81.1 months versus 54.2 months with crizotinib, a final median PFS of 34.8 versus 10.9 months, a 5-year OS rate of 62.5% versus 45.5%, and a median duration of response of 42.3 versus 11.1 months (HR 0.41) establishing overwhelming long-term superiority in both disease control and survival in previously untreated advanced ALK-positive NSCLC. |
84% Reduction in CNS Progression Risk Superior Intracranial Disease Control Across Advanced and Early-Stage Settings In the ALEX trial, alectinib reduced the risk of CNS progression or death by 84% versus crizotinib (HR 0.16; 95% CI 0.10–0.28; p<0.0001), reflecting its exceptional blood-brain barrier penetration. In the adjuvant ALINA trial, alectinib reduced CNS disease-free survival events by 78% versus platinum chemotherapy (HR 0.22; 95% CI 0.08–0.58), achieving a 4-year CNS DFS rate of 90.4% versus 76.1% demonstrating consistent intracranial disease control in both metastatic and resected ALK-positive NSCLC across the full disease continuum. |
76% Reduction in Recurrence Risk in Adjuvant Setting First-Ever ALK TKI Approval for Resected Early-Stage NSCLC The Phase III ALINA trial established alectinib as the first adjuvant ALK TKI approved for resected ALK-positive NSCLC: adjuvant alectinib for two years reduced the risk of disease recurrence or death by 76% versus platinum-based chemotherapy (HR 0.24; 95% CI 0.13–0.43; p<0.0001) in patients with completely resected stage IB (≥4 cm) to IIIA disease translating a landmark survival benefit previously seen in the metastatic setting into a curative-intent adjuvant strategy for eligible early-stage patients. |
Dosage and Administration of Alecinix 150 MG (Alectinib)
Administration Rule Must Be Taken With Food: Alectinib must be taken with food. Swallow Alecinix 150 MG capsules whole with water. Do not open, break, or chew the capsules. The standard dose of 600 mg twice daily is achieved by taking four 150 mg capsules (four Alecinix 150 MG capsules) twice daily, approximately 12 hours apart at the same times each day, with meals. If a dose is missed and it is within 6 hours of the scheduled dose time, take the missed dose with food and resume the normal schedule; if more than 6 hours have elapsed, skip the missed dose and take the next scheduled dose at the usual time with food. Do not double the dose to compensate for a missed one.
Advanced ALK-Positive NSCLC (First-Line and Crizotinib-Pretreated) Standard Dose (600 mg Twice Daily, Continuous): The reference label recommends 600 mg twice daily (BID) on a continuous schedule for all advanced NSCLC indications, including first-line treatment-naïve ALK-positive advanced NSCLC and ALK-positive advanced NSCLC previously treated with crizotinib. Four Alecinix 150 MG capsules taken twice daily approximately 12 hours apart with food deliver the full 1,200 mg total daily dose validated across the ALEX, J-ALEX, ALESIA, and ALUR Phase II/III trial programmes. Alectinib is continued until disease progression or unacceptable toxicity. There is no distinct loading dose or planned de-escalation schedule in the approved dosing regimen.
Adjuvant Setting (Resected Stage IB to IIIA ALK-Positive NSCLC) 600 mg Twice Daily for Two Years: In the adjuvant setting, the reference label specifies 600 mg twice daily for a total treatment duration of two years following complete tumour resection, consistent with the ALINA Phase III trial protocol. Treatment should begin within 12 weeks of surgery and after recovery from surgical procedures. Adjuvant treatment is discontinued upon disease recurrence, unacceptable toxicity, or completion of the two-year treatment period, whichever occurs first.
Dose Reduction Schedule for Toxicity Management: If alectinib-related adverse events require dose modification including Grade 3 or greater haematological toxicity, hepatotoxicity, ILD/pneumonitis, symptomatic bradycardia, severe myalgia, or Grade 4 CPK elevation the reference label specifies a stepwise reduction: first to 450 mg twice daily (three 150 mg capsules twice daily), then to 300 mg twice daily (two 150 mg capsules twice daily) if further reduction is necessary. Dose modifications are guided by the treating oncologist based on NCI Common Terminology Criteria for Adverse Events (CTCAE) grading. Permanent discontinuation is required for Grade 4 ILD/pneumonitis or recurrent severe toxicity not resolving to Grade 1 or baseline following two stepwise dose reductions.
Dose Adjustment for Strong CYP3A4 Inhibitors and Inducers: Alectinib is primarily metabolised by CYP3A4. When a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir-based antiretroviral regimens) must be co-administered, close monitoring for alectinib-related adverse events is required and dose adjustment should be guided by the treating oncologist. Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, St John’s Wort) significantly reduce alectinib plasma concentrations and should be avoided where clinically feasible. Consult the treating oncologist before initiating or discontinuing any concomitant medication that may interact with CYP3A4 pathways.
Clinical Monitoring Requirements During Alecinix 150 MG (Alectinib) Treatment
Liver function monitoring is the primary biochemical safety requirement for alectinib therapy. The reference label mandates liver function tests (ALT, AST, and total bilirubin) assessment every 2 weeks during the first 3 months of treatment, then once monthly and as clinically indicated thereafter. ALT or AST elevation greater than 5 times the upper limit of normal (ULN) with total bilirubin ≤2× ULN, or total bilirubin elevation greater than 3× ULN, requires treatment interruption until recovery to Grade 1 or baseline with permanent discontinuation required if Grade 3 or 4 hepatotoxicity recurs. Alectinib is also a substrate and inhibitor of P-glycoprotein (P-gp) and BCRP transporters; patients receiving concomitant P-gp substrates with narrow therapeutic windows (e.g., digoxin, dabigatran) require close clinical surveillance.
Cardiac monitoring for bradycardia is required throughout the treatment period. Symptomatic bradycardia defined as a resting heart rate below 60 beats per minute has been reported in approximately 11% of alectinib-treated patients. Heart rate and blood pressure should be assessed at baseline and at regular intervals; dose interruption is required for symptomatic Grade 2 or 3 bradycardia with review and adjustment of all concomitant medications known to cause bradycardia (e.g., beta-blockers, non-dihydropyridine calcium channel blockers). Pulmonary surveillance for interstitial lung disease (ILD) and pneumonitis including assessment for new or worsening dyspnoea, cough, fever, or radiological changes should form part of every oncology review, as serious ILD/pneumonitis has been reported in alectinib-treated patients.
Any suspected ILD/pneumonitis requires immediate treatment interruption pending investigation, with permanent discontinuation for Grade 3 or 4 events. Creatine phosphokinase (CPK) monitoring is also recommended Grade 3 or 4 CPK elevation (greater than 5× ULN), often accompanied by severe myalgia or musculoskeletal pain, requires treatment interruption until recovery to Grade 1 or baseline. Photosensitivity surveillance should be discussed with all patients before treatment initiation, as photosensitivity reactions have been reported patients should be advised to limit sun exposure, use protective clothing, and apply broad-spectrum sunscreen throughout the treatment period.
Drug Interactions and Important Safety Information for Alecinix 150 MG (Alectinib)
The most clinically significant drug interactions for alectinib involve inhibitors and inducers of CYP3A4, the primary cytochrome P450 enzyme responsible for alectinib metabolism. Strong CYP3A4 inhibitors including ketoconazole, itraconazole, voriconazole, clarithromycin, and ritonavir-based antiretroviral regimens significantly increase alectinib and its active metabolite M4 plasma exposure, potentially elevating systemic toxicity risk; close monitoring for adverse events including elevated liver enzymes, bradycardia, CPK elevation, and ILD is required during co-administration and dose adjustment should be guided by the treating oncologist. Strong CYP3A4 inducers including rifampicin, carbamazepine, phenytoin, and St John’s Wort substantially decrease alectinib plasma concentrations and the reference label recommends avoiding these combinations entirely where clinically feasible, as sub-therapeutic alectinib exposure may compromise disease control in a treatment setting where continuous ALK inhibition is required for durable disease suppression.
A second clinically important interaction class involves P-glycoprotein (P-gp) substrates. Alectinib and its active metabolite M4 are inhibitors of P-gp and BCRP transporters; co-administration with P-gp substrates with narrow therapeutic windows including digoxin and dabigatran may increase the exposure and toxicity of these agents and requires close clinical surveillance and, where appropriate, dose adjustment of the P-gp substrate in consultation with the treating oncologist. Medications known to cause bradycardia including beta-adrenergic blocking agents, non-dihydropyridine calcium channel blockers (diltiazem, verapamil), ivabradine, and antiarrhythmic agents can potentiate alectinib-associated bradycardia and require careful cardiac monitoring and clinical reassessment throughout the combination treatment period. Patients must inform their oncologist of all concomitant medications including over-the-counter drugs, herbal supplements, antacids, gastric acid-reducing agents, and any agents known to affect cardiac conduction before and during Alecinix 150 MG treatment. Those requiring additional targeted, cytotoxic, or supportive oncology agents alongside alectinib can contact the Mediaid Pharmacy team for sourcing; the full range of oncology medicines available for worldwide dispatch is listed on the Mediaid Pharmacy website.
Side Effects and Precautions of Alecinix 150 MG (Alectinib)
|
Common Side Effects Fatigue and asthenia (approximately 41% of patients the most frequently reported adverse event across clinical trial programmes; predominantly Grade 1–2) Constipation (~35%; a common gastrointestinal class effect of alectinib, typically manageable with dietary modification and laxative prophylaxis) Peripheral oedema (~28%; predominantly Grade 1–2 oedema of the extremities, face, or periorbital region) Myalgia (~29%) and arthralgia (musculoskeletal pain; may accompany CPK elevation in some patients) Nausea (~22%) and vomiting Elevated liver transaminases ALT and AST requiring scheduled liver function monitoring throughout treatment Photosensitivity reactions (sun-exposed skin rash or burning; sun avoidance and broad-spectrum sunscreen use are mandatory throughout treatment) Anaemia (Grade 1–2 haemoglobin reduction; less common than with chemotherapy but requires periodic haematological assessment) Weight gain and increased appetite |
Serious Warnings and Precautions Interstitial lung disease (ILD) and pneumonitis: serious ILD/pneumonitis, including fatal cases, have been reported. Any new or worsening respiratory symptoms dyspnoea, cough, or fever during alectinib therapy require immediate treatment interruption and clinical investigation. Permanent discontinuation is required for Grade 3 or 4 ILD/pneumonitis. Hepatotoxicity: Grade 3 or 4 ALT/AST elevations have been reported. Liver function tests are required every 2 weeks for the first 3 months, then monthly and as clinically indicated. Permanent discontinuation is required for recurrent Grade 3 hepatotoxicity or any Grade 4 hepatotoxicity event. Symptomatic bradycardia: new-onset symptomatic bradycardia (heart rate below 60 bpm) has been reported in approximately 11% of alectinib-treated patients. Routine heart rate and blood pressure monitoring is required at baseline and at each scheduled clinical review throughout treatment; all concomitant chronotropic medications require careful assessment. Severe myalgia and CPK elevation: Grade 3 or 4 CPK elevation (greater than 5× ULN) has been reported. Assess CPK levels every month for the first 3 months and as clinically indicated; treatment interruption is required for Grade 3 or 4 events until recovery to Grade 1 or baseline. Embryo-fetal toxicity: alectinib can cause fetal harm based on its mechanism of action and non-clinical studies. Females of reproductive potential must use effective contraception during treatment and for 1 week after the final dose. Males with female partners of reproductive potential must use contraception during treatment and for 3 months after the last dose. Breastfeeding is not recommended during treatment and for 1 week after the final dose. |
Who Should Use Alecinix 150 MG (Alectinib)?
Alecinix 150 MG (Alectinib) is the reference-label standard unit-dose capsule for adults with ALK-positive advanced NSCLC in the first-line setting, for adults with ALK-positive advanced NSCLC previously treated with crizotinib, and since April 2024 for adults who have undergone complete tumour resection of stage IB (≥4 cm) to IIIA ALK-positive NSCLC requiring adjuvant targeted therapy. All three indications require prior confirmation of ALK-positive NSCLC status using an approved diagnostic test (e.g., VENTANA ALK (D5F3) CDx assay or an FDA-approved NGS panel) alectinib must not be initiated in the absence of documented ALK rearrangement.
The 600 mg twice-daily continuous dose (four 150 mg capsules twice daily with food) is the dose validated across the ALEX, J-ALEX, ALESIA, ALUR, and ALINA Phase II/III trial programmes ensuring that every prescription initiated with Alecinix 150 MG is grounded in Level 1 clinical evidence. Oncologists and thoracic oncology specialists assess baseline liver function (ALT/AST/total bilirubin), heart rate, pulmonary status, photosensitivity risk, CPK levels, and all relevant concomitant medications particularly strong CYP3A4 inhibitors or inducers, P-gp substrates with narrow therapeutic windows, and chronotropic agents before initiating Alecinix 150 MG. Patients who are pregnant, breastfeeding, or of reproductive potential require individualised risk counselling and contraceptive guidance before treatment begins. For patients requiring complementary targeted therapies or supportive oncology treatments alongside alectinib, Mediaid Pharmacy’s oncology specialty medicines range provides a broad selection of approved agents available for global delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Alecinix 150 MG (Alectinib)
Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines with worldwide shipping. Alecinix 150 MG (Alectinib) is available in a 120’s capsule pack manufactured by Beacon Pharmaceuticals Ltd., and all orders are supported by pricing quotations, stock confirmation, regulatory documentation, and end-to-end delivery tracking. Hospitals, specialist thoracic oncology and medical oncology clinics, distributors, and patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all enquiries about Alecinix 150 MG Alectinib stock, pricing, and international delivery timelines. Buyers sourcing multiple oncology or lung cancer medicines in a single shipment can browse the complete lung cancer medicines collection before requesting a consolidated quotation.
Why Choose Alecinix 150 MG (Alectinib) from Mediaid Pharmacy?
Alecinix 150 MG (Alectinib) provides thoracic oncology and medical oncology teams with a 150 mg alectinib capsule in a 120’s pack the unit-dose strength that anchored the ALEX trial (final median OS 81.1 months vs 54.2 months with crizotinib; 5-year OS 62.5% vs 45.5%; final median PFS 34.8 vs 10.9 months), the ALINA adjuvant trial (DFS HR 0.24; p<0.0001; 76% reduction in recurrence risk; CNS DFS HR 0.22; 4-year CNS DFS 90.4% vs 76.1%), and the ALESIA Phase III trial confirming consistent efficacy in Asian ALK-positive NSCLC patients with a 5-year OS rate of 66.4%. The 600 mg twice-daily continuous schedule achieved by taking four 150 mg capsules twice daily with food is the reference-label standard for alectinib across all approved indications, ensuring every initiated prescription is grounded in validated, published Phase II/III evidence across more than 92,000 patients treated with alectinib in clinical practice globally.
Manufactured by Beacon Pharmaceuticals Ltd. (Bangladesh), Alecinix is an accessible oncology-grade capsule formulation suitable for patients requiring continuous, twice-daily ALK inhibition with documented CNS penetration in both the advanced metastatic and adjuvant early-stage setting. Mediaid Pharmacy supplies Alecinix 150 MG in 120’s capsule packs with full product documentation, specialist supply support, and worldwide shipping from Dhaka. Every order begins with a prescription-based enquiry that maintains supply aligned with clinical need. To compare alectinib with other targeted thoracic oncology or oncology agents, or to source additional ALK-positive NSCLC therapies, visit the Mediaid Pharmacy oncology medicines section and contact the team for a personalised quotation.
Frequently Asked Questions About Alecinix 150 MG (Alectinib)
What is Alecinix 150 MG (Alectinib) used for?
Alecinix 150 MG (Alectinib) is an oral, second-generation ALK tyrosine kinase inhibitor (TKI) used to treat ALK-positive non-small cell lung cancer (NSCLC) in adults. It is indicated for the first-line treatment of adults with ALK-positive advanced NSCLC, for adults with ALK-positive advanced NSCLC previously treated with crizotinib, and following FDA approval in April 2024 for adjuvant treatment of adults following complete tumour resection of stage IB (tumours ≥4 cm) to IIIA ALK-positive NSCLC. Alectinib works by potently inhibiting the ALK kinase domain blocking the downstream RAS/ERK, PI3K/AKT, and JAK/STAT3 signalling cascades that drive malignant cell survival and proliferation in ALK-rearranged NSCLC while also retaining activity against the majority of known crizotinib-resistant ALK secondary mutations. Its exceptional CNS penetration enables effective suppression of intracranial ALK-driven disease, a key differentiating clinical advantage in a tumour type where brain metastases develop in a high proportion of patients.
What is the generic name of Alecinix 150 MG?
The generic name of Alecinix 150 MG is alectinib INN. Alecinix 150 MG is a capsule formulation available in a 120’s pack (120 capsules per pack), manufactured by Beacon Pharmaceuticals Ltd., Bangladesh. The originator reference brand for alectinib is Alecensa, developed and commercialised by Roche and Genentech, and approved in the United States, the European Union, and other major international markets for first-line and crizotinib-pretreated ALK-positive advanced NSCLC and for adjuvant ALK-positive NSCLC following resection.
What is the standard dose of Alecinix 150 MG (Alectinib) for ALK-positive NSCLC?
The dose must always be determined by the treating oncologist. The reference label recommends 600 mg twice daily (BID) on a continuous schedule for all approved advanced NSCLC indications of alectinib including first-line ALK-positive advanced NSCLC, crizotinib-pretreated ALK-positive advanced NSCLC, and adjuvant post-resection treatment (administered for two years). This 600 mg twice-daily dose is achieved by taking four Alecinix 150 MG capsules twice daily (totalling eight 150 mg capsules per day, or 1,200 mg alectinib daily) always with food to ensure adequate drug absorption. If adverse events require dose modification, the reference label specifies stepwise reductions: first to 450 mg twice daily (three capsules twice daily), then to 300 mg twice daily (two capsules twice daily) if further reduction is necessary. Never change your dose without explicit direction from your prescribing oncologist.
What strengths and pack sizes is Alecinix (Alectinib) available in?
Alecinix is available as a 150 mg capsule in a 120’s pack (120 capsules per pack), manufactured by Beacon Pharmaceuticals Ltd., Bangladesh. Contact Mediaid Pharmacy for current stock availability, pricing, and worldwide shipping details for Alecinix 150 MG Alectinib.
What are the side effects of Alecinix 150 MG (Alectinib)?
Common side effects of alectinib 150 mg include fatigue (~41%), constipation (~35%), myalgia (~29%), peripheral oedema (~28%), nausea (~22%), elevated liver transaminases (ALT/AST), photosensitivity reactions, weight gain, anaemia, and symptomatic bradycardia (~11%). Serious but less frequent adverse effects include interstitial lung disease (ILD) and pneumonitis (including fatal cases), Grade 3 or 4 hepatotoxicity, severe CPK elevation with associated myalgia (Grade 3 or 4 events in a subset of patients), symptomatic bradycardia requiring dose interruption, and embryo-fetal toxicity. Mandatory liver function monitoring (every 2 weeks for the first 3 months, then monthly), heart rate assessment, CPK monitoring (monthly for the first 3 months), and photosensitivity precautions are required throughout the treatment period. Consult your prescribing oncologist regarding your individual risk profile before and during treatment.
Does Alecinix 150 MG (Alectinib) penetrate the brain and treat CNS metastases?
Yes. Alectinib achieves cerebrospinal fluid (CSF) concentrations approximating estimated free plasma concentrations, reflecting its well-characterised blood-brain barrier penetration. This CNS pharmacokinetic advantage translates directly into significantly reduced rates of intracranial disease progression versus crizotinib in Phase III trials: in the ALEX trial, alectinib reduced the risk of CNS progression or death by 84% versus crizotinib (HR 0.16; 95% CI 0.10–0.28; p<0.0001). In the adjuvant ALINA trial, alectinib reduced CNS disease-free survival events by 78% versus platinum chemotherapy (HR 0.22; 95% CI 0.08–0.58), achieving a 4-year CNS DFS rate of 90.4% versus 76.1% with chemotherapy positioning alectinib as the preferred ALK TKI for patients at risk of or with established CNS involvement.
How often are monitoring tests required during Alecinix 150 MG (Alectinib) treatment?
The reference label requires liver function tests (ALT, AST, and total bilirubin) every 2 weeks for the first 3 months of treatment, then once monthly and as clinically indicated thereafter. CPK levels and clinical assessment of musculoskeletal symptoms should be conducted monthly for the first 3 months, then as clinically indicated. Heart rate and blood pressure assessment for symptomatic bradycardia should be incorporated into every scheduled oncology review. Clinical evaluation for respiratory symptoms suggestive of ILD/pneumonitis and photosensitivity reactions should form part of each clinical assessment throughout the treatment course. All monitoring should be guided by the treating oncologist based on each patient’s individual clinical course, comorbidities, and concomitant medications.
Is Alecinix 150 MG (Alectinib) safe during pregnancy or while breastfeeding?
No. Alectinib can cause fetal harm based on its mechanism of action and non-clinical reproduction studies. Females of reproductive potential must use effective contraception during treatment with Alecinix 150 MG and for at least 1 week after the final dose. Males with female partners of reproductive potential must use contraception during treatment and for at least 3 months after the last dose. Breastfeeding is not recommended during treatment and for 1 week after the final dose. Speak with your prescribing oncologist before starting treatment if you are pregnant, planning a pregnancy, or currently breastfeeding.
Can I order Alecinix 150 MG (Alectinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Alecinix 150 MG (Alectinib) to patients and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order Alecinix 150 MG (Alectinib) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.